Press Releases
Date picker
Category
Results per page
Notice of Extraordinary General Meeting Kancera AB
Regulatory
Aktieägarna i Kancera AB (publ) kallas härmed till extra bolagsstämma torsdagen den 10 november 2011 kl. 16.00 på Kilpatrick Townsend Advokatbyrås kontor, Hovslagargatan 5B, 5 tr i Stockholm.
iNovacia AB has developed active compounds as a step towards treatment of a serious parasitic disease
iNovacia, an internationally established contract research company owned by Kancera AB (Nasdaq OMX Stockholm First North, KAN), announces today that highly potent inhibitors of a target protein in the parasite…
Kancera has filed patent for new active substances against cancer
Kancera reports that the company has registered an international patent application (PCT/EP2011/066250) for a new class of compounds targeting the energy metabolism of cancer cells. This new class of synthetic…
Breakthrough for the Kancera ROR Technology Against Incurable Cancer
Kancera has in collaboration with scientists at the Karolinska Institute identified active compounds that effectively kill pancreatic cancer cells. Annually over 100 000 people are diagnosed with pancreatic cancer in…
Interim Report for Kancera AB (publ)
Regulatory
January 1 - June 30, 2011 All figures relate to the Kancera Group unless otherwise specified. Kancera's acquisition of iNovacia AB was completed on February 17, 2011 and iNovacia AB's…
Kancera Implements Rights Issue to Develop the Company´s ROR Technology
Regulatory
Kancera is announcing today that the company has raised SEK 7.6m before issue costs in a rights issue. The capital raised will be used to further develop the company's ROR…
Kancera’s ROR Technology to Attack Solid Tumors
At a cancer seminar in Båstad tomorrow, July 7, Professor Håkan Mellstedt will present the basis for further development of Kancera's ROR technology for the purpose of attacking solid tumors…
iNovacia Further Develops its Compound Collection
iNovacia, the drug discovery service provider and subsidiary of Kancera AB (Nasdaq OMX Stockholm First North, KAN), today announced the addition of over 20,000 novel compounds to its small-molecule screening…
Interim Report Q1 2011 for Kancera AB (publ)
Regulatory
January 1 - March 31, 2011 This Interim Report covers the period January 1 - March 31, 2011. As Kancera was established on April 28, 2010, there are no historical…
The Annual General Meeting of Kancera AB
Regulatory
The Annual General Meeting of Kancera AB was held in Stockholm on 26 May, 2011.Annual Report and discharge from liabilityThe Company’s Income Statement and Balance Sheet were adopted and the…